# T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

> **NCT02326974** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 164 (actual)

## Conditions studied

- HER-2 Positive Breast Cancer
- Breast Cancer
- Stage II Breast Cancer
- Stage III Breast Cancer

## Interventions

- **DRUG:** T-DM1
- **DRUG:** Pertuzumab
- **PROCEDURE:** Excision of tumor/mastectomy

## Key facts

- **NCT ID:** NCT02326974
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-01
- **Primary completion:** 2018-06
- **Final completion:** 2028-01
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326974, "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02326974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*